Stay updated on Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page now includes a Barcelona location under the Locations section and the revision is updated to v3.3.3, while the prior Barcelona Locations entry and the HHS Vulnerability Disclosure link have been removed.SummaryDifference0.2%

- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe page now displays Revision: v3.3.2 after the prior v3.2.0, an internal version update that does not affect user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedRemoved the government funding lapse notice from the page, an administrative banner that does not affect the study details or data presented. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check67 days agoChange DetectedNo meaningful changes detected in the Study Details page for NCT03276013 (Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer).SummaryDifference0.5%

- Check96 days agoChange DetectedMajor update: adds a government funding and operating status notice and marks the page as revision v3.2.0, replacing v3.1.0.SummaryDifference3%

- Check103 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0, indicating a new release with updated revision metadata.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page.